Alto Neuroscience (ANRO) Competitors $2.94 +0.10 (+3.33%) Closing price 05/22/2025 03:59 PM EasternExtended Trading$2.90 -0.04 (-1.53%) As of 05/22/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANRO vs. RNAC, TSVT, ALMS, INZY, GLUE, TERN, PVLA, LFCR, TNGX, and GOSSShould you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Alumis (ALMS), Inozyme Pharma (INZY), Monte Rosa Therapeutics (GLUE), Terns Pharmaceuticals (TERN), Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR), Tango Therapeutics (TNGX), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry. Alto Neuroscience vs. Cartesian Therapeutics 2seventy bio Alumis Inozyme Pharma Monte Rosa Therapeutics Terns Pharmaceuticals Palvella Therapeutics Lifecore Biomedical Tango Therapeutics Gossamer Bio Alto Neuroscience (NYSE:ANRO) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, community ranking, dividends and earnings. Do insiders & institutionals believe in ANRO or RNAC? 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 11.1% of Alto Neuroscience shares are owned by insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation & earnings, ANRO or RNAC? Alto Neuroscience has higher earnings, but lower revenue than Cartesian Therapeutics. Alto Neuroscience is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlto NeuroscienceN/AN/A-$36.31M-$2.34-1.26Cartesian Therapeutics$34.17M6.95-$219.71M-$52.83-0.17 Does the MarketBeat Community prefer ANRO or RNAC? Cartesian Therapeutics received 23 more outperform votes than Alto Neuroscience when rated by MarketBeat users. Likewise, 95.12% of users gave Cartesian Therapeutics an outperform vote while only 80.00% of users gave Alto Neuroscience an outperform vote. CompanyUnderperformOutperformAlto NeuroscienceOutperform Votes1680.00% Underperform Votes420.00% Cartesian TherapeuticsOutperform Votes3995.12% Underperform Votes24.88% Does the media refer more to ANRO or RNAC? In the previous week, Alto Neuroscience had 6 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 19 mentions for Alto Neuroscience and 13 mentions for Cartesian Therapeutics. Alto Neuroscience's average media sentiment score of 0.64 beat Cartesian Therapeutics' score of 0.42 indicating that Alto Neuroscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more risk & volatility, ANRO or RNAC? Alto Neuroscience has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Is ANRO or RNAC more profitable? Alto Neuroscience has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat Alto Neuroscience's return on equity.Company Net Margins Return on Equity Return on Assets Alto NeuroscienceN/A -49.28% -33.52% Cartesian Therapeutics -510.72%N/A -6.03% Do analysts prefer ANRO or RNAC? Alto Neuroscience presently has a consensus target price of $15.40, indicating a potential upside of 422.92%. Cartesian Therapeutics has a consensus target price of $42.50, indicating a potential upside of 364.48%. Given Alto Neuroscience's higher probable upside, analysts clearly believe Alto Neuroscience is more favorable than Cartesian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Cartesian Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryCartesian Therapeutics beats Alto Neuroscience on 10 of the 17 factors compared between the two stocks. Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANRO vs. The Competition Export to ExcelMetricAlto NeurosciencePharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$79.73M$6.47B$5.33B$19.30BDividend YieldN/A2.64%5.21%3.83%P/E Ratio-1.269.0626.7134.53Price / SalesN/A251.51386.0834.83Price / CashN/A65.8538.2517.51Price / BookN/A6.456.774.69Net Income-$36.31M$143.98M$3.23B$1.02B7 Day Performance20.70%2.41%1.80%-1.74%1 Month Performance31.41%4.56%11.10%7.50%1 Year Performance-76.04%-2.67%17.11%4.15% Alto Neuroscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANROAlto Neuroscience1.7019 of 5 stars$2.95+3.3%$15.40+422.9%-76.0%$79.73MN/A-1.26N/ANews CoverageAnalyst RevisionRNACCartesian Therapeutics1.5293 of 5 stars$10.37+1.1%$42.50+309.8%-64.1%$269.14M$34.17M-0.2064News CoverageAnalyst RevisionGap UpTSVT2seventy bio1.5355 of 5 stars$5.00flat$4.25-15.0%N/A$266.15M$48.37M-2.69440Positive NewsALMSAlumis2.2312 of 5 stars$5.95+5.9%$24.86+317.8%N/A$265.38MN/A0.00N/AGap DownINZYInozyme Pharma3.0315 of 5 stars$3.99+1.0%$11.75+194.5%-15.4%$257.60MN/A-2.5650High Trading VolumeGLUEMonte Rosa Therapeutics2.1238 of 5 stars$4.11+3.3%$15.50+277.1%-3.8%$252.81M$159.49M-2.2590Positive NewsAnalyst DowngradeTERNTerns Pharmaceuticals4.0922 of 5 stars$3.15+9.4%$15.63+396.0%-50.4%$251.53MN/A-2.6740News CoveragePositive NewsPVLAPalvella Therapeutics3.7974 of 5 stars$22.56+2.3%$46.29+105.2%N/A$249.13M$42.81M-1.86N/AAnalyst RevisionLFCRLifecore Biomedical1.1994 of 5 stars$6.71-2.6%$8.00+19.2%+14.4%$248.44M$130.31M-11.98690News CoverageAnalyst ForecastGap UpTNGXTango Therapeutics1.878 of 5 stars$2.29+52.7%$12.33+438.6%-74.8%$248.22M$40.99M-1.9490Positive NewsHigh Trading VolumeGOSSGossamer Bio3.75 of 5 stars$1.09+4.8%$7.75+611.0%+81.7%$247.67M$114.70M-3.41180Analyst Revision Related Companies and Tools Related Companies Cartesian Therapeutics Competitors 2seventy bio Competitors Alumis Competitors Inozyme Pharma Competitors Monte Rosa Therapeutics Competitors Terns Pharmaceuticals Competitors Palvella Therapeutics Competitors Lifecore Biomedical Competitors Tango Therapeutics Competitors Gossamer Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANRO) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANRO Stock Free ANRO Stock Alerts